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The long-term course of cyclosporine-associated chronic nephropathy.
We evaluated a chronic renal injury in 37 cardiac transplant recipients
treated for 12 to 24 months with cyclosporine (CsA). Twenty-four
cardiac transplant recipients treated with azathioprine for more than 24
months served as controls. Despite equivalent cardiac performance,
GFR in those treated with CsA was depressed, 47 3 versus 94 4
ml/min/l.73 m2 (P < 0,001). CsA therapy was also associated with
significant elevation of renal vascular resistance (RVR), proteinuria,
arterial hypertension, and impaired intrarenal conversion of inactive
prorenin to active renin. Histopathological changes associated with
CsA included an obliterative arteriolopathy with deposition of protein-
aceous material in necrotic arteriolar walls, and associated tubulointer-
stitial damage. A minority of glomerbuli exhibited either ischemic
collapse or sclerosis. Area perimeter analysis revealed enlargement of
the remaining glomeruli with significant expansion of the mesangium.
Longitudinal examination over a 48 month period (N = 15) during
which CsA was reduced in dosage or withdrawn revealed persistent
hypofiltration, increasingly elevated RVR and heavier proteinuria.
Further histopathological deterioration was observed when renal tissue
was sampled a second time in six patients, and three members of the
experimental group developed end-stage renal disease. We conclude
that continuous CsA therapy for more than 12 months causes a chronic
injury to renal microvessels that is rarely reversible and potentially
progressive.
Cyclosporine A (CsA) has been used to suppress cardiac
allograft rejection at our institution since December 1980, two
years after its introduction into clinical medicine as an im-
munosuppressive agent [1]. Although graft survival was en-
hanced, it soon became apparent that chronic administration of
CsA was associated with the development of a chronic renal
injury. Careful study of renal function and structure in patients
who had received CsA therapy for 12 months revealed a
substantial decline in the glomerular filtration rate (GFR),
accompanied by patchy collagenisation of glomeruli and the
tubulointerstitial compartment [2, 3].
In the hope that the diminished mortality and improved
well-being associated with CsA would be maintained, we have
continued to immunosuppress cardiac transplant recipients
with this agent, albeit at progressively lower dosages. To
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elucidate the nature and outcome of the chronic renal injury
associated with protracted CsA therapy we have extended our
earlier series of observations [2, 31. We have enlarged both in
scope and number measurements of renal function in patients
receiving CsA for 12 or 24 months, and attempted to relate
these to alterations in renal morphology. We have also sub-
jected a subset of our CsA treated population to a longitudinal
examination over a 48 month period. Our cross-sectional ob-
servations reveal that at the relatively high dosage used in the
initial part of this study, CsA therapy of 12 to 24 months
duration leads to a severe injury of renal microvessels. Our
longitudinal observations indicate that this chronic microvascu-
lar injury is not reversed by either late reduction of dosage or
even complete withdrawal of CsA therapy.
Methods
Patient populations
Routine clinical and laboratory determinations were made at
yearly intervals in each of 100 patients who received consecu-
tive cardiac transplants between December 1980 and April
1984, when CsA combined with prednisone was the standard
immunosuppressive regimen at our institution. CsA was initi-
ated with an oral loading dose of 17 mg/kg directly before the
transplantation and lowered postoperatively to an average dose
of 10 mg/kg per 24 h by the end of the first month. Subsequent
maintenance CsA therapy was adjusted to achieve trough levels
of immunoassayable CsA in serum between 100 and 300 nglml
(through May 1984) or 50 to 150 ng/ml (June 1984 and thereaf-
ter). Control observations were made in 100 patients who
received consecutive cardiac transplants between April 1976
and December 1980 when azathioprine combined with predni-
sone was used to suppress allograft rejection.
Approximately one half of the available members of each
group were selected arbitrarily for a detailed examination of
renal function using physiological techniques. Of 73 CsA treated
recipients surviving for two years beyond transplantation, 37
were subjected to physiologic study after 12 or 24 months of
therapy. Forty-seven patients treated under the earlier azathi-
oprine regimen were alive when we commenced our study in
February 1983, and 24 of these were selected for physiologic
study. No criteria other than patient willingness to participate
and the availability of a team of investigators were used in
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selecting the subgroups for detailed study. The subgroups did
not differ with respect to age (36 1 vs. 38 1 years in CsA vs.
azathioprine recipients), sex distribution, or etiology of the
original heart disease. Neither was the prevailing serum creat-
mine level at the time of transplantation different in the two
groups, 1.3 0.1 versus 1.4 0.1 mg/dl, respectively.
Physiologic studies
It is routine procedure at our institution to admit cardiac
transplant recipients to a clinical research center at yearly
intervals for evaluation of cardiac allograft function. This
evaluation includes determination of cardiac output according
to the Fick method, and measurement of hydraulic pressures in
the cardiac chambers, superior vena cava and femoral artery.
During the 27 months from February 1, 1983, to May 1985, the
selected patients of the two subgroups described above, also
underwent a detailed physiologic study of renal function during
their annual evaluation. Of the 37 CsA-treated patients se-
lected, 20 had received their cardiac allograft one year previ-
ously, while the remaining 17 had been transplanted two years
earlier. The 24 members of the azathioprine-treated control
population were undergoing their third through fifth annual
examination of cardiac allograft function. The study protocol,
previously approved by the institutional review board at Stan-
ford University, was described in detail to all patients before
admission, and informed consent to perform the study was
obtained in each instance. Antihypertensive and diuretic drugs
were discontinued for four days before admission in all patients
receiving such therapy.
Before transferring patients to the cardiac catheterization
laboratory, each was studied according to a urinary clearance
technique that has been described in detail elsewhere [2]. In
brief, blood was drawn first after the patient had remained
supine overnight for estimation of hematocrit level, plasma
oncotic pressure and examination of the renin-angiotensin
system. Clearances of inulin and paraaminohippuric acid (PAH)
were then performed with the subject voiding spontaneously
after a diuresis had been established by oral water loading. The
GFR was calculated as the urinary clearance of inulin averaged
for each of four collection periods, and corrected for body
surface area. The corresponding urinary clearance of PAH
divided by the renal PAH-extraction ratio, was equated with
renal plasma flow. The renal extraction ratio of PAH was
determined immediately after completing the urinary clearances
(during subsequent cardiac cathei-ization) by sampling blood
simultaneously from the femoral artery and the right renal vein.
Renal vascular resistance was calculated by dividing the pres-
sure drop from femoral artery to vena cava by renal blood flow,
where the latter has been computed from renal plasma flow and
the fractional hematocrit.
The concentrations of inulin and PAH were determined with
an automated assay that has been described previously [2].
Plasma oncotic pressure was determined directly by membrane
osmometry [3]. To permit accurate assay of albumin and
immunoglobulin G (IgG) in unconcentrated urine, their respec-
tive concentrations were measured by a sensitive, enzyme-
linked immunosorbent assay. Urine samples were placed in
polystyrine wells coated with buffered antibodies to human
albumin or IgG. Goat anti-human albumin or IgG conjugated
with alkaline phosphatase was then added, followed by alkaline
phosphatase substrate (Sigma Chemical Co. St. Louis, Mis-
souri, USA). The color change was read from a standard curve
on an optical densitometer at 490 nm (Micro-elisa Reader MR
600A, Dynatech Laboratories, Inc. Alexandria, Virginia, USA).
Plasma was thawed immediately before assay of plasma
renin. Plasma renin activity was assayed as angiotensin I
released from angiotensinogen during incubation of plasma at
37°C and pH 7.4. A renal renin secretion ratio (Sr) was calcu-
lated as
Sr = [Vr] [Ar][Ar]
where [Vr] is plasma renin activity of renal venous blood, and
[Ar] the corresponding value in femoral arterial blood. Addi-
tional aliquots of peripheral venous plasma were incubated with
sheep angiotensinogen before and after dialysis to pH 3.3, to
estimate active and total renin. Inactive renin activated at pH
3.3 was calculated as the difference between total and active
renin [4].
Morphometric analysis
Twelve CsA-recipients agreed to undergo a renal biopsy on
the day following the physiologic studies. Tissue was processed
for light and fine structural study. For light microscopy the
Zenker's fixed tissues were serially sectioned and stained with
hematoxylin and eosin, PAS-alcian blue and Masson trichrome
stains. Tubulointerstitial and vascular lesions were analyzed
semiquantitatively, where 0 was no abnormality; 1 + to 4+ for
vascular lesions, minimal to marked; and 1 to 4+ for tubuloin-
terstitial lesions reflect the percentage of area of available tissue
exhibiting tubular atrophy and interstitial fibrosis; 1 + was
<25%, 2 + was 25 to 50%, 3 + was 50 to 75%, and 4 + was
>75%. The outline of each glomerular tuft in three to five
PAS-alcian blue stained sections per case was traced onto a
digitizing tablet and its cross-sectional area determined by area
perimeter analysis using the SMI micro-comp computerized
system (Southern Micro Instruments Inc., Atlanta, Georgia,
USA).
For electron microscopy tissue was fixed in gluteraldehyde,
embedded in epon and stained with lead citrate. Survey sec-
tions were used to locate three glomeruli in each biopsy core
that exhibited neither sclerosis nor ischemic collapse. Sixty to
70 nanometer sections of selected glomeruli were photographed
at x 1000 and x 4000 and subjected to area perimeter analysis,
as described in detail elsewhere [5]. Widening of the basement
membrane was evaluated by determining the ratio of the total
area-to-length of the glomerular basement membrane in each
peripheral capillary loop. Changes in epithelial podocytes were
assessed by counting the number of epithelial filtration slits per
1000 micrometers of capillary loop length. Finally, the fraction
of total glomerular cross-sectional area occupied by mesangium
was determined.
Renal tissue obtained from 10 living kidney donors was from
Dr. Michael Steffes of the Department of Laboratory Medicine
and Pathology at the University of Minnesota Hospital, Minne-
apolis, Minnesota, USA. All glomeruli in PAS-alcian blue
stained sections of each biopsy were subjected to computerized
area perimeter analysis at x 1000 magnification to provide
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Table 1. Clinical features
Azathioprine Cyclosporine
Months post-transplant Months post-transplant
1 6 12 24 1 6 12 24
Number surviving 94 63 59 50 95 84 82 73
Immunosuppressive 1,3 0.1 1.7 0.1 1.7 0.1 1.8 0.1 10.0 0.4 7.4 0.4 6.3 0.3 5.3 0.3
dosage
mg/kg/24 hr
Prednisone dosage 1.01 0.03 0.50 0.03 0.39 0.02 0.29 0.02 0.47 O.03 0.23 0.02a 0.18 o.ola 0.16 0.0l
mg/kg/24 hr
Number on 0 1 3 3 53 66 66 62
antihypertensives
Systolic BP 115 1 121 2 119 2 125 2 129 2 134 2 138 2 140 2
Diastolic BP 72 1 83 1 83 2 84 2 81 IU 92 ia 96 1 99 2
Serum creatinine 1.0 0.1 1.2 0.1 1.2 0.1 1.2 0.0 1.3 0.l 1.9 o.la 2.1 o.Ia 2.0 o.la
mg/dl
Blood urea 27 1 22 1 20 I 18 1 39 2 42 ia 43 2 42 2
nitrogen mg/di
a Significantly different (P < 0,05) from corresponding value in azathioprine group
control values for glomenilar tuft cross-sectional area. Two
glomeruli from each biopsy were then prepared for electron
microscopy as described above to provide control values for the
ultrastructural morphometric quantities of interest.
Longitudinal examination
Fifteen CsA recipients examined initially 12 (N = 9) or 24
months (N = 6) after cardiac transplantation were restudied
with identical physiologic techniques at the time of their routine
36 and 48 month, follow-up examinations. Sequential morpho-
logical observations were also made in six of the patients who
had earlier undergone a renal biopsy. Four were members of the
longitudinally studied group who exhibited increasing GFR at
their 36 or 48 month sequential study. Renal tissue in the
remaining two subjects was obtained at autopsy.
Statistical analysis
The significance of differences between the CsA and azathi-
oprine subgroups, and of changes during the longitudinal study
of CsA recipients was examined with an analysis of variance
(ANOVA) using the CLINFO system.
Results
Clinical and Laboratory Findings
The 24 month outcome of cardiac transplantation in the 100
patient cohort treated with CsA is compared to that of the 100
patients treated earlier with azathioprine in Table 1. Patient
survival was higher throughout in the CsA than in the azathi-
oprine treated group, despite substantially lower maintenance
doses of prednisone in the former, Whereas the need for
antihypertensive agents was deemed rare in the azathioprine
treated group, such therapy was administered within a month of
transplantation to a majority, and by 12 or 24 months to more
than 80% of CsA treated recipients. Antihypertensive therapy
notwithstanding, average systolic blood pressure exceeded that
in the azathioprine group by 13 to 19 mm Hg at each observa-
tion period; the corresponding excess of average diastolic blood
pressure in the CsA group was by 9 to 15 mm Hg. The high
prevalence of arterial hypertension in CsA treated recipients
Table 2. Initia1 physiologic findings
Azathioprine Cyclosporine
recipients recipients P
N=24 N=37 value
Serum creatinine mgidl 1.0 0.04 1.8 0.09 <0.001
Glomerular filtration rate 94 4 47 3 <0.001
mI/mm/I .73 in2
PAH extraction ratio 0.87 0.02 0.75 0.02 <0.001
Renal plasma flow 450 24 284 19 <0.001
mi/mini] .73 m2
Filtration fraction 0.22 0.01 0.16 0.01 <0.001
Afferent oncotic pressure 21.0 0.5 21.6 0.5 NS
mm Hg
Mean arterial pressure mm Hg 98 2 115 2 <0.001
Renal vascular resistance units 126 7 272 31 <0.001
Cardiac output liter/mm 5.8 0.3 5.7 0.2 NS
Renal blood flow/cardiac 15.9 1.2 8.8 0.6 <0.001
output %
Urinary albumin excretion 27 14 132 57 <0.01
/.Lg/min
Urinary IgG excretion g/mnin 1.7 0.6 7.8 2.5 <0.02
was accompanied by chronic azotemia. Whereas mean serum
creatinine and blood urea nitrogen levels were within the
normal range at all observation points in the azathioprine group,
corresponding values were elevated at all time points in the CsA
group.
Physiologic findings
On initial physiologic examination the 37 selected CsA recip-
ients were receiving 6.1 0.5 mg/kg per 24 hours and the trough
level of immunoassayable CsA in serum was 164 18 ng/ml.
Their physiologic findings are compared to those of azathio-
prine treated controls in Table 2.The cardiac output in the two
groups was not different, 5.7 0.2 versus 5.8 0.3 liter/mm.
Nevertheless, the GFR was reduced by half in the CsA recipi-
ent group, 47 3 versus 94 4mllmin per 1.73 m2 (P < 0.001).
Although renal plasma flow was reduced in parallel, glomerular
underperfusion alone cannot account entirely for the lowered
GFR. This is indicated by a significantly depressed filtration
fraction, 0.16 0.01 versus 0.22 0.01 (P < 0.001).
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Azathioprine
recipients
Cyclosporine
recipientsa P value
Plasma renin activityb ng/ml/hr 3.6 1.3 1.1 0.3 0.05
Renin secretion ratio 0.31 0.10 0.44 0.13 NS
Total renin ng/ml/hr 182 43 230 44 0.05
Active reninb ng/m!/hr 14.6 4.6 5.9 0.7 <0.01
Inactive renin" ng/ml/hr 167 39 224 44 <0.02
Inactive/active remn 13.3 1.5 27.8 3.5 <0.01
Additional evidence of glomerular injury in CsA recipients
was a modest elevation of urinary albumin excretion rate above
the azathioprine control level, 132 57 versus 27 14 tg!min
(P < 0.01). A corresponding increase in urinary IgG excretion
rate was also observed, 7.8 2.5 versus 1.7 0.6 gImin (P <
0.02). Afferent oncotic pressure (which is taken to be the same
as in peripheral venous blood) was similar in the two groups,
but mean arterial pressure in CsA recipients was elevated by 17
mm Hg above that in those receiving azathioprine (P < 0.001).
Renal vascular resistance was twofold elevated in CsA recipi-
ents, 272 31 versus 126 7 (mm Hg . mm) per liter in
azathioprine recipients (P < 0.001). That increased resistance in
the renal vascular bed associated with CsA therapy was rela-
tively selective is indicated by the corresponding percentage of
cardiac output perfusing the kidneys in the two groups, 8.8
0.6 versus 15.9 1.2%, respectively.
In keeping with earlier reports, plasma renin activity and
inactive renin remained strikingly elevated (4.2 1.2 and 403
102 nglml per hr) in eight members of the CsA group who had
been receiving therapy with captopril [6, 71, even though
antihypertensive therapy had been withdrawn four days previ-
ously. When these eight subjects were excluded, plasma renin
activity was lower in CsA than Aza recipients, 1.1 0.3 versus
3.6 1.3 nglml per hr (P = 0.05, Table 3). In contrast the renal
renin secretion ratio was similar in the two groups, 0.44 0.13
versus 0.31 0.10, respectively. When taken together with the
37% reduction of renal plasma flow however, the latter finding
suggests that the renal production rate of active renin was, if
anything, lower in CsA than azathioprine recipients. Total
plasma renin concentration was high in both groups, due largely
to a striking three- to fivefold increase in inactive renin above
normal levels (Table 3). CsA recipients differed from azathiop-
rifle controls however, in that active renin was significantly
lower, while the opposite was true of inactive renin. These
differences are reflected by a twofold elevation (P < 0.01) of the
inactive:active plasma renin ratio in CsA versus azathioprine
recipients (27.8 3.5 and 13.3 1.5, respectively), and suggest
that chronic CsA therapy is associated with a partial block in
the intrarenal conversion of inactive prorenin to active renin.
Morphology
Light microscopy. The light microscopic findings in the 12
initial biopsy samples are included in Table 4 (cases 1 to 12).
Glomeruli in 9 of the 12 instances exhibited global or segmental
sclerosis involving from 2 to 34% of the glomeruli (Fig. lA). In
Months
Case Source on CsA GFR GS% IG% CTI HYA CsA-AA JGA
la BXI 24 39 0 0 1+ 1+ 0 3+
lb BX2 48 53 10 24 2+ 1+ 2+ 0
2a BX1 24 33 0 18 2+ 0 0 1+
2b BX2 48 40 15 33 2+ 2+ 3+ 1+
3a BX1 12 32 5 0 2+ 0 0 1+
3b BX2 24 34 15 9 3+ 1+ 0 0
4a BXI 24 52 9 36 1+ 4+ 3+ 0
4b BX2 36 68 18 46 2+ 4+ 3+ 0
5a BX1 12 52 5 14 2+ 1+ 1+ 1+
5b AUT 19 ? 11 15 1+ 0 1+ 2+
6a BXI 24 16 18 18 2+ 1+ 1+ 0
6b AUT 28 0 23 30 2+ 2+ 2+ 3+
7 BXI 12 37 34 56 3+ 1+ 2+ 0
8 BX1 24 28 25 17 1+ 1+ 1+ 0
9 BXI 12 33 3 0 1+ 1+ 2+ 1+
10 BX1 48 33 2 38 3+ 2+ 2+ 1+
11 BX1 36 45 8 6 2+ 2+ 2+ 1+
12 BX1 24 50 0 0 1+ 1+ 1+ 2+
13 BX1 60 15 76 9 3+ 3+ 3+ 0
14 AUT 12 0 12 80 2+ 1+ 1+ 1+
15 BX1 9 17 20 25 3+ 1+ 2+ 1+
Abbreviations are: BX, biopsy; AUT, autopsy; GFR, glomerular filtra-
tion rate; GS, glomerulosclerosis; IG, ischemic glomerular collapse;
CT!, tubular atrophy, interstitial fibrosis; HYA, arteriolar hyalinosis;
CsA-AA, cyclosporine-associated arteriolopathy; JGA, juxtaglomeru-
lar apparatus hyperplasia. In cases 1-6, a is initial and b is follow-up
examination.
keeping with the increased synthesis of inactive prorenin,
striking juxtaglomerular apparatus hyperplasia was evident in
eight patients. Collapsed glomeruli which appeared smaller than
normal were prominent in 9 of the 12 biopsies, comprising 6 to
56% of all glomeruli in these biopsy cores (Fig. 1B). Six
hundred sixty-five glomerular cross sections were available for
morphometric analysis in the 12 biopsy cores of CsA recipients,
while the corresponding number of glomerular cross sections in
normal control tissue was 731. The distribution of glomerular
tuft cross-sectional area in CsA-treated patients is compared to
that of normal controls in Figure 2. Tuft area was distributed
around a mode of 12000 j2 in the control group. However, the
rather bell-shaped distribution apparent in controls was lost in
CsA recipients. The percentage of glomeruli with cross sec-
tional area below the mode was increased in CsA recipients (53
vs. 45% in controls) reflecting presumably collapsed and scle-
rosed glomeruli. A corresponding increase in glomerular tufts of
cross sectional area above 20000 t2 (11 vs. 4%) suggests that
spared, remnant glomeruli had become enlarged (Fig. 1).
There were subtle to conspicuous arteriolar abnormalities in
all but one case (Fig. 3). These consisted of subintimal and
medial hyalin deposits indistinguishable from the hyalin depos-
its seen in the afferent and efferent arterioles of diabetic,
hypertensive and nephrotic patients (Fig. 3A). There were also
frequent examples of the fibrointimal thickening and elastic
membrane replication encountered as age related and hyperten-
sive phenomena. The former occurred in eleven and the latter in
seven of the cases. A more distinctive vascular lesion, the
so-called CsA-associated arteriolopathy, involved the afferent
arterioles [8]. This appeared as an extensive eosinophilic,
lumpy and smudgy deposit which replaced the pericytes of the
arteriole. When minimal, its appearance was similar to the
Table 3. Renin angiotensin system Table 4. Histopathologic features of cyclosporine nephrotoxicity
a Eight cyclosporine recipients receiving antihypertensive treatment
with captopril have been excluded from the analysis.
b Normal supine values in aged-matched healthy individuals on ad
libitum diet are: plasma renin activity 0.1—2.2, active renin 0.4—14.0,
and inactive renin 11—49 ng/ml/hr, respectively.
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Fig. 1. A. Global glomerular sclerosis
(PAS-alcian blue x 200). B. Small glomeruli
that had undergone ischemic collapse
(PAS-alcian blue x 400) were prevalent in
both first and second biopsies. Some
glomeruli that have escaped these changes
appear to have undergone hypertrophy.
hyalin deposit commonly associated with diabetes mellitus, but
when conspicuous, its appearance was more distinctive (Fig.
SB). In most cases individual pericytes showed considerable
anisonucleosis (Figs. 1A, 3A), and in some the media was
nearly devoid of pericytes even when smudgy deposits were
inconspicuous. An additional feature was the finding of karyor-
rhectic debris in the media in three cases. Fibrinoid necrosis
and fibrin thrombosis of vessels were not observed in any of the
cases.
Associated with the glomerular sclerosis, ischemic glomeru-
lar tufts and vascular lesions were variable tubular atrophy,
interstitial fibrosis and chronic inflammation (Figs. 1 and 3). In
some cases the changes were nearly diffuse, but most exhibited
narrow stripes of atrophy and fibrosis, apparently correspond-
ing to areas of cortex associated with arteriolar lesions.
Electron microscopy. Three glomeruli exhibiting no evidence
of either sclerosis or collapse at x 1000 magnification were
selected from each biopsy core. Electron photomicrographs
were then subjected to area perimeter analysis. The ratio of
basement membrane area to total length of all glomerular
capillary loops in the tuft was slightly but not significantly
increased above control values, 0.54 0.02 versus 0.49 0.01
(P NS) suggesting only mild thickening of the glomerular
basement membrane. Similarly a patchy broadening of epithe-
hal foot processes lowered slightly the frequency of filtration
slits to 1.0 0.04 per 1000 micrometers of capillary loop length
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Fig. 2. Distribution of surface area of 731 glomeru/ar cross sections in
biopsy cores of JO controls (upper histogram) is compared to that of 665
glo,nerular cross sections in first biopsy cores of 12 recipients who had
received CsA for between 12 and 24 mont/is (lower histogram). Note
glomerular cross-sectional area is shifted towards both smaller and
larger size in CsA treated recipients.
versus 1.2 0.07 in controls (P = NS). A diffuse expansion of
the mesangium reflecting matrix more than cellular compo-
nents, constituted the most striking ultrastructural alteration.
Fractional mesangial area varied from 0.16 to 0.20 in the 10
control glomeruli, but exceeded 0.20 in glomeruli of all but two
CsA recipients (Fig. 4, range 0.14 to 0.39). On average, frac-
tional mesangial area was increased significantly, 0.23 0.02
versus 0.17 0.007 (P < 0.01). Because total cross-sectional
area of selected glomeruli was larger in CsA recipients than
controls, we infer that chronic administration of CsA is char-
acterized by a generalized accumulation of mesangial matrix in
glomeruli that have neither collapsed nor undergone global
sclerosis.
Longitudinal findings
Fifteen patients studied initially at 12 or 24 months were
reexamined at 36 and again at 48 months post-transplant. Their
physiologic findings are summarized in Table 5. CsA was
withdrawn because of severe renal insufficiency and replaced
by azathioprine in one instance after 18 months and in an
additional three cases after 36 months. In the remaining patients
CsA dose was lowered progressively from an initial dose of 6.8
0.6 to 4.5 0.5 and 3.1 0.6 mg/kg per 24 hours, by 36 and
48 months, respectively. The corresponding trough levels of
CsA in serum declined, in parallel, from 175 23 to 118 21
and 66 16 ng/ml, respectively. Judged by a trend towards
increasing cardiac output and declining left atrial pressure,
cardiac performance improved in the interim. Despite with-
drawal or reduction of CsA and improving cardiac perform-
ance, renal plasma flow tended to be lower and renal vascular
resistance higher at the two follow-up examinations. GFR
remained constant at 56 4, 54 7 and 55 5 ml/min per 1.73
m2, perhaps facilitated by a significant decline in serum protein
concentration with a corresponding decline in average plasma
oncotic pressure by 1.3 to 1.5 mm Hg at follow-up examination.
Arterial pressure remained elevated throughout, 118 4 mi-
tially and 115 4 and 116 4 mm Hg at 36 and 48 months,
respectively.
Inspection of the individual determinations of GFR in Figure
5 reveals quite large fluctuations in this quantity over a 48
month period, suggesting a functional component to the hypo-
filtration. However, only occasional examples of GFR entering
the control (azathioprine recipient) range were encountered.
Moreover, GFR failed to return to the control range in the four
patients in whom CsA was withdrawn completely (dashed lines,
Fig. 5). In fact, GFR declined below earlier values in two of
these latter subjects despite withdrawal of CsA, indicating fixed
and progressive injury to glomeruli. In keeping with progressive
glomerular injury, increasing proteinuria of variable magnitude
became manifest (Fig. 6). On average, the excretion rate of
albumin increased significantly from an initial value of 162 70
to 396 164 at 36 months (P < 0.05) and 546 300 g/min at
48 months (P < 0.01). Corresponding increases were observed
also in the urinary excretion rate of IgG, from 6 2 to 21 7
(P < 0.01) and 53 43 p.glmin (P < 0.05), suggesting increasing
impairment of glomerular barrier size-selectivity with the pas-
sage of time [5].
A subsequent tissue sample was obtained 6 to 24 months after
the initial biopsy in cases I through 6 (Table 4). There was
evidence of progressive renal damage without exception. An
increase was observed in the percentage of glomeruli exhibiting
either sclerosis (6.2 6.7 to 15.3 4.8%; P < 0.001) or
ischemic collapse of the tuft (14.7 12.5 to 24.2 13.5; P <
0.02). Atrophic tubular changes and interstitial fibrosis also
increased (1.5 0.5 to 2.0 0.6; P = NS). CsA-associated
arteriolopathy became manifest or more conspicuous between
the two examinations in four of six instances (0.5 0.5 to 1.8
1.2; P < 0.05); there was a parallel increase in arteriolar
hyalinosis. Particularly noteworthy is that the four patients
subjected to repeat biopsy (cases I to 4, Table 4) were selected
because the GFR was actually slightly higher at the time of the
second biopsy. Notwithstanding the modestly improved level of
GFR, the second biopsy revealed a substantial increase in the
percentage of glomeruli that had undergone either sclerosis or
ischemic collapse. Thus serial measurement of the GFR does
not appear to reflect reliably a progressive obliteration and
sclerosis of the cortical microvascular bed in the kidneys of
patients receiving CsA.
Development of end-stage renal disease
Three of the 37 member CsA subgroup subjected to physio-
logical study have since developed end-stage renal failure. One
(case #6, Table 4) examined on a single occasion after 24
months of CsA treatment, required dialysis after 26 months.
The second, (case #8, Table 4 and depicted by the lowest
recorded GFR at 36 and 48 months in Fig. 5) received a renal
transplant after 50 months. The third, (case #13, Table 4) was
found to have the most extensive glomeruloscierosis and arteri-
olopathy in our entire series. His biopsy was performed 79
months following transplantation, the first 60 of which were
associated with continuous CsA therapy. Although azathiop-
rifle was substituted for CsA after 60 months, his renal function
continues to deteriorate and he is currently being prepared for
a renal transplantation.
Of the remaining 63 cardiac allograft recipients treated with
CsA and not subjected to physiological study during the course
8
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Fig. 3. A. The appearance of arteriolar hyalinosis is due to
deposits of PAS positive material in a subintimal location
(PAS-alcian blue x 400). B An example of CsA-
arteriolopathy is demonstrated, in which the PAS positive
material is seen replacing pericytes (PAS-alcian blue x
640).
of this study, 33 are known to have survived more than two
years at the time of writing. Two of these have documented
evidence of having developed end-stage renal disease requiring
dialysis therapy. One (case #14, Table 4) had histopathologic
features at autopsy similar to those observed in biopsy material
from our study population. The second (case #15, Table 4) was
biopsied at another center because of declining renal function
after nine months of CsA therapy. Review of the tissue revealed
platelet-fibrin thrombi in glomerular capillaries and arterioles
consistent with the hemolytic-uremic syndrome. Although this
process appears to be idiosyncratic, it is well recognized as an
adverse effect of CsA on the kidney [91. Thus, there was a small
but definite risk of early progression to end-stage renal disease
within four years among cardiac transplant recipients treated
chronically with CsA. In contrast, chronic renal failure pro-
gressing to end-stage renal disease has never been observed
among 148 cardiac transplant recipients treated only with
azathrioprine and prednisone at this institution between 1969
and 1980.
Discussion
A large body of evidence indicates that the daily use of CsA
for 12 months or longer is associated with a chronic renal injury.
Most experience with the protracted use of CsA has been in
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Control CsA treated
glomeruli glomeruli
Fig. 4. Fraction of glomerular tuft cross-sectional area occupied by
mesangium in glomeruli of control (left) and GsA-treated recipients
(right).
Initial
12 or 24
months 36 Months 48 Months
CsA dose mglkg/24 hr
CsA trough ng/ml
6.8 0.6
175 23
4•5 Ø5C
118 21"
3.1 0.6"
66 161
Cardiac output liter/mm 5.8 0.2 6.1 0.4 6.3 0.3a
Left atrial pressure 12 1 10 1 8 ia
mm Hg
GFR ml/min/1.73 m2 56 4 54 7 55 5
Renal plasma flow
ml/min/1.73 m2
312 13 272 30 293 43
Renal vascular 212 8 265 3P 249 40
resistance
(mmHg . min)/ml
Meanarterialpressure 118±4 115±4 116±4
mm Hg
Afferent oncotic 22.6 0.5 21.1 06b 21.3 0,6
pressure mm Hg
Serum protein 6.5 0.1 6.0 0.1" 6.0 0.1"
concentration g/ dl
Urinary albumin 162 70 396 164" 546 300'
excretion
Urinary IgG excretion 6 2 21 7C 53 43b
0.05 > P <0.1 vs. initial study
"P < 0.05 vs. initial study
P < 0.01 vs. initial study
"P < 0.001 vs. initial study
renal allograft recipients, in whom the differentiation of CsA
nephropathy from chronic allograft rejection has been difficult
[8, 10]. However, a chronic renal injury with characteristics
similar to those described in the present study has been
reported also in liver allograft recipients [11] and in patients
with uveitis [12], who like cardiac allograft recipients, have
healthy native kidneys. The absence of discernable chronic
renal damage in the foregoing patient categories when treated
by alternative immunosuppressive regimens, suggests that CsA
therapy itself is responsible for the renal injury.
Fig. 5. Serial determinations of GFR in 15 GsA-treated cardiac trans-
plant recipients. The shaded area is the range exhibited by azathioprine
treated controls. Dashed lines reflect intervals and examinations fol-
lowing withdrawal of CsA therapy in four cases.
Fig. 6. Serial urinary excretion rate of albumin A and immunoglobulin
G B in 15 GsA-treated recipients. Dashed lines reflect intervals and
examinations following withdrawal of CsA therapy in four cases. Note
differences in the logarithmic scales on each ordinate.
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Table S. Longitudinal physiologic findings
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12or24 36 48
Time, months post-transplant
C0
0)
x
C
12or24 36 48 12or2436 48
Time, monthspost-transplant
The dosage of CsA employed by us perioperatively, and the
maintenance doses used in the first two years of our experience
with this agent, are today regarded by many as excessive. Of
note however, the use of similar dosing schedules in two large
multicenter trials in renal transplant recipients was associated
also with persistent elevation of the mean serum creatinine level
[13, 14]. On the basis of a rather stable average level of
azotemia in these, and other large groups of renal transplant
recipients beyond two years of therapy, it has been argued that
a progression of chronic nephropathy does not occur in patients
receiving CsA in doses comparable to those used by us [13—16].
Our finding that average GFR remains stable, albeit severely
depressed, for up to 48 months of CsA treatment, explains the
above-cited constancy of the level of azotemia. The demonstra-
tion of a chronically stable level of glomerular hypofiltration
does not appear to rule out progressive renal injury, however.
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Our histopathologic observations suggest that the cortical mi-
crovasculature undergoes progressive damage and obliteration
with continuous administration of CsA beyond 12 months.
Artenolar abnormalities including pencyte hypertrophy, necro-
sis and replacement of the wall with proteinaceous deposits are
most likely the result of CsA-induced vasospasm. Irreversible
ischemic damage appears to occur following replacement of the
media by fibrous tissue, with secondary damage to glomeruli
and tubular loss [8]. In keeping with this possibility is our
demonstration of a trend towards higher renal vascular resis-
tance between 24 and 36 months of therapy (Table 5). RYR
failed to increase further between 36 and 48 months, during
which interval CsA was discontinued in three patients. This
finding suggests that elevated arteriolar resistance is in part
attributable to functional vasospasm as well as to luminal
obliteration.
Withdrawal of CsA after a few months of therapy has been
associated with reversal of azotemia [17, 18]. Even when serum
creatinine levels have remained unchanged, withdrawal of CsA
after less than 12 months of therapy has been shown to be
followed by an increase in renal plasma flow [19]. The disparity
between these short term findings and our observation of a late
increase in renal vascular resistance can be reconciled if renal
vasospasm early in the course of CsA therapy gives way, with
the passage of time, to a structural obliteration of the renal
cortical vascular bed.
The relative constancy of GFR despite an apparently progres-
sive obliteration of cortical microvessels is intriguing. It sug-
gests that the single nephron GFR of remnant glomeruli that
remain perfused is adaptively increased, thereby compensating
for the declining number of functional nephrons. In keeping
with this hypothesis, some preserved glomeruli in our biopsy
material were larger than normal (Fig. 2). Like remnant glomer-
uli of the rat following extensive ablation of renal mass [20],
they also exhibited a generalized expansion of mesangial matrix
(Fig. 4), increasing leakiness of their capillary walls to large
plasma proteins (Fig. 6) and ultimately, increasing sclerosis
(Table 4). Whether arterial hypertension is also an expression of
a declining number of nephrons, or a consequence of a direct
action of CsA on the systemic vasculature to elevate peripheral
resistance, cannot be determined. Transmission of elevated
arterial pressure to glomerular capillaries has been a consistent
feature of remnant glomeruli however, and has been incrimi-
nated in driving the selerosing process in surviving glomeruli
121—23].
Short term studies in the rat suggest that CsA can activate the
renin-angiotensin system acutely, and that• this vasopressor
system may play an initiating role in the genesis of CsA
associated nephropathy [24, 25]. Our finding of extreme eleva-
tion of plasma inactive renin (which closely resembles prorenin)
and of total plasma renin, together with prominent hyperplasia
of juxtaglomerular apparati, is consistent also with a more
chronic stimulation of the renin-angiotensin system (Table 3).
In keeping with other reports however, we do not find hyper-
tension late in the course of the renal injury to be associated
with enhanced plasma renin activity [26—28]. The combination
of increased synthesis of prorenin with a limited release of
active renin could be explained by a partial block in the
intrarenal conversion of the prohormone to active renin. Of
interest, the combination of high plasma inactive renin with
normal or low active renin is also found in the sclerosing
glomerulopathy of diabetes mellitus [4, 291, a condition charac-
terized by a diffuse expansion of mesangial matrix and artenolar
hyalinosis like that observed with chronic CsA therapy.
An especially discouraging feature of our longitudinal study is
that chronic renal injury, once established, cannot be reversed
by either substantial reductions in the dosage of CsA or even its
complete withdrawal. That the chronic nephropathy may in fact
be progressive is suggested by our serial histopathological
observations and by the development of end-stage renal disease
in S of 73 CsA-treated recipients, who have survived cardiac
transplantation for two years or longer. Since it takes typically
more than a decade for a variety of chronic renal injuries to
destroy the kidney, it could be that these isolated examples
represent merely the vanguard of patients with CsA-associated
chronic nephropathy who are destined to progress irrevocably,
but more slowly, to end-stage renal disease. In light of this
potential outcome, it is germane to question whether the rapidly
proliferating use of CsA outside of the field of organ transplan-
tation is justified. The dilemma posed by such expanded use of
CsA is well exemplified by therapeutic trials in two immuno-
logic disorders that have the potential to be complicated by
sclerosing glomerulopathy, namely type I diabetic insulitis and
minimal change nephropathy [30—32]. Glomerulosclerosis (ini-
tially focal) leading ultimately to end-stage renal disease is
likely to occur in only a very small minority of patients with
minimal change nephropathy [33], and only after a decade or
more in fewer than 50% of type I diabetics [34]. Because these
disorders recur promptly when CsA is withdrawn, protracted or
even permanent administration of this agent is likely to be
required [32, 35]. Although it is possible that therapeutic
efficacy can be achieved at lower doses than those used in the
first part of the present study, it remains to be demonstrated
convincingly that lower dosage schedules are free of long-term,
nephrotoxic effects [361. Based on our present knowledge, it is
by no means certain that CsA induced injury will not lead to
end-stage renal disease more rapidly and commonly than the
aforementioned diseases, a therapeutic outcome that would
clearly be self-defeating.
The uncertainty surrounding the ultimate outcome on the
kidney of long-term CsA therapy is heightened by the lack of a
non-invasive procedure with which to monitor possible progres-
sion of the renal injury. Our experience indicates that in most
instances accurate, repeated determinations of the GFR may
not rule out a progressing injury. Although more discriminating,
even invasive procedures such as renal biopsy and the deter-
mination of renal vascular resistance are problematic. The
former is subject to error because random samples of the renal
cortex may not reflect accurately the injurious process, which
has a patchy distribution. The need to catheterize the renal vein
so as to estimate PAH extraction reliably precludes the use of
PAH clearance alone to determine renal vascular resistance.
PAH extraction by chronically damaged kidneys of the present
study was impaired and unpredictable, spanning a range of 0.48
to 0.96 and averaging 0.78.
We recommend that researchers intensify their efforts to
better characterize the course and dose dependency of CsA-
associated chronic nephropathy, to seek clinically applicable
methods to detect unusually susceptible subjects at especially
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high risk of a lethal renal injury, and to find ways to safely
convert recipients of stable allografts from CsA to other forms
of immunosuppression within a year of transplantation. In the
meantime, we propose that the use of CsA be limited to
recipients of allografts and those with immunologically-media-
ted diseases that are sufficiently severe to threaten life in the
near term.
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